Evidence map›Paper›PMID 33967735›Full record

ArticleFrontiers in aging neuroscience2021

DHCR24 Knock-Down Induced Tau Hyperphosphorylation at Thr181, Ser199, Thr231, Ser262, Ser396 Epitopes and Inhibition of Autophagy by Overactivation of GSK3β/mTOR Signaling.

Xiaojing Bai, Junfeng Wu, Mengqi Zhang, Yixuan Xu, Lijie Duan, Kai Yao, Jianfeng Zhang, Jimei Bo, Yongfei Zhao, Guoxiong Xu and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. 3Oncology research · 2025
    Article
  7. Article
  8. Review
  9. Article
  10. Towards a Unitary Hypothesis of Alzheimer's Disease Pathogenesis.Journal of Alzheimer's disease : JAD · 2024
    Article
  11. Autophagy markers, cognitive deficits and depressive symptoms in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. ExploitingFrontiers in genetics · 2023
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Xiaojing BaiDepartment of Neurology, Jinshan Hospital, Fudan University, Shanghai, China.
Junfeng WuDepartment of Neurology, Jinshan Hospital, Fudan University, Shanghai, China.
Mengqi ZhangDepartment of Neurology, Jinshan Hospital, Fudan University, Shanghai, China.
Yixuan XuDepartment of Neurology, Jinshan Hospital, Fudan University, Shanghai, China.
Lijie DuanDepartment of Neurology, Jinshan Hospital, Fudan University, Shanghai, China.
Kai YaoDepartment of Neurology, Jinshan Hospital, Fudan University, Shanghai, China.
Jianfeng ZhangDepartment of Neurology, Jinshan Hospital, Fudan University, Shanghai, China.
Jimei BoDepartment of Neurology, Jinshan Hospital, Fudan University, Shanghai, China.
Yongfei ZhaoDepartment of Neurology, Jinshan Hospital, Fudan University, Shanghai, China.
Guoxiong XuThe Research Center for Clinical Medicine, Jinshan Hospital, Fudan University, Shanghai, China.
Hengbing ZuDepartment of Neurology, Jinshan Hospital, Fudan University, Shanghai, China.
Jinshan Hospital of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accumulating evidences supported that knock-down of DHCR24 is linked to the pathological risk factors of AD, suggesting a potential role of DHCR24 in AD pathogenesis. However, the molecular mechanism link between DHCR24 and tauopathy remains unknown. Here, in order to elucidate the relationship between DHCR24 and tauopathy, we will focus on the effect of DHCR24 on the tau hyperphosphorylation at some toxic sites. In present study, we found that DHCR24 knock-down significantly lead to the hyperphosphorylation of tau sites at Thr181, Ser199, Thr231, Ser262, Ser396. Moreover, DHCR24 knock-down also increase the accumulation of p62 protein, simultaneously decreased the ratio of LC3-II/LC3-I and the number of autophagosome compared to the control groups, suggesting the inhibition of autophagy activity. In contrast, DHCR24 knock-in obviously abolished the effect of DHCR24 knock-down on tau hyperphosphrylation and autophagy. In addition, to elucidate the association between DHCR24 and tauopathy, we further showed that the level of plasma membrane cholesterol, lipid raft-anchored protein caveolin-1, and concomitantly total I class PI3-K (p110α), phospho-Akt (Thr308 and Ser473) were significantly decreased, resulting in the disruption of lipid raft/caveola and inhibition of PI3-K/Akt signaling in silencing DHCR24 SH-SY5Y cells compared to control groups. At the same time, DHCR24 knock-down simultaneously decreased the level of phosphorylated GSK3β at Ser9 (inactive form) and increased the level of phosphorylated mTOR at Ser2448 (active form), leading to overactivation of GSK3β and mTOR signaling. On the contrary, DHCR24 knock-in largely increased the level of membrane cholesterol and caveolin-1, suggesting the enhancement of lipid raft/caveola. And synchronously DHCR24 knock-in also abolished the effect of DHCR24 knock-down on the inhibition of PI3-K/Akt signaling as well as the overactivation of GSK3β and mTOR signaling. Collectively, our data strongly supported DHCR24 knock-down lead to tau hyperphosphorylation and the inhibition of autophagy by a lipid raft-dependent PI3-K/Akt-mediated GSK3β and mTOR signaling. Taking together, our results firstly demonstrated that the decrease of plasma membrane cholesterol mediated by DHCR24 deficiency might contribute to the tauopathy in AD and other tauopathies.

Indexed as

Alzheimer's disease 3/autophagyCholesterolDHCR24GSK3βhyperphosphorylationmTORPI3-K

Identifiers

PMID33967735
PMCPMC8098657
OpenAlexW3154763858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.